Literature DB >> 18431069

Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth.

Massimo Montalto1, Luca Santoro, Sara Dalvai, Valentina Curigliano, Ferruccio D'Onofrio, Emidio Scarpellini, Giovanni Cammarota, Simona Panunzi, Antonella Gallo, Antonio Gasbarrini, Giovanni Gasbarrini.   

Abstract

BACKGROUND/AIMS: Small intestinal bacterial overgrowth (SIBO) is defined by any condition in which the proximal part of the small bowel harbors for a long time > 10(5) bacteria/ml of the intestinal juice. No data are currently available about direct or indirect parameters indicating the presence of leukocytes in the gut wall and mucosal neutrophil turnover in patients with SIBO. In our pilot study we evaluate fecal calprotectin concentrations (FCC) in patients with SIBO in order to identify a possible presence of subclinical intestinal inflammation.
METHODS: 40 consecutive patients with SIBO resulting positive to hydrogen glucose breath test, and 40 adult healthy volunteers were included in the study. FCC were determined by ELISA. Mean FCC were compared by means of the t-test for independent samples.
RESULTS: FCC in patients with SIBO were not significantly different compared to controls (p = 0.907).
CONCLUSION: Our study shows for the first time that FCC in patients with SIBO do not significantly differ from controls, suggesting that in SIBO there are no intestinal subclinical inflammatory changes involving principally the neutrophils. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18431069     DOI: 10.1159/000116777

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  11 in total

1.  Does calprotectin level identify a subgroup among patients suffering from irritable bowel syndrome? Results of a prospective study.

Authors:  Chloé Melchior; Moutaz Aziz; Typhaine Aubry; Guillaume Gourcerol; Muriel Quillard; Alberto Zalar; Moïse Coëffier; Pierre Dechelotte; Anne-Marie Leroi; Philippe Ducrotté
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 2.  Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice.

Authors:  Eliza Lężyk-Ciemniak; Magdalena Tworkiewicz; Dominika Wilczyńska; Anna Szaflarska-Popławska; Aneta Krogulska
Journal:  Med Princ Pract       Date:  2020-10-29       Impact factor: 1.927

3.  All that glitters is not always gold.

Authors:  E Harrison; S Hayes; L Howell; S Lal
Journal:  BMJ Case Rep       Date:  2014-02-10

4.  Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study.

Authors:  Michael Manz; Emanuel Burri; Claude Rothen; Nuschin Tchanguizi; Christian Niederberger; Livio Rossi; Christoph Beglinger; Frank Serge Lehmann
Journal:  BMC Gastroenterol       Date:  2012-01-10       Impact factor: 3.067

5.  Diagnostic yield of endoscopy in patients with abdominal complaints: incremental value of faecal calprotectin on guidelines of appropriateness.

Authors:  Emanuel Burri; Michael Manz; Patricia Schroeder; Florian Froehlich; Livio Rossi; Christoph Beglinger; Frank Serge Lehmann
Journal:  BMC Gastroenterol       Date:  2014-03-29       Impact factor: 3.067

6.  The concentration of calprotectin in the stools of children with diagnosed cystic fibrosis.

Authors:  Sabina Więcek; Halina Woś; Bożena Kordys-Darmolińska; Magda Sankiewicz-Szkółka; Urszula Grzybowska-Chlebowczyk
Journal:  Prz Gastroenterol       Date:  2016-03-30

7.  Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patients.

Authors:  Su Yeong Kim; Na Mi Lee; Sin Weon Yun; Soo Ahn Chae; In Seok Lim; Eung Sang Choi; Dae Yong Yi
Journal:  Korean J Pediatr       Date:  2019-07-03

8.  Faecal levels of calprotectin in systemic sclerosis are stable over time and are higher compared to primary Sjögren's syndrome and rheumatoid arthritis.

Authors:  Kristofer Andréasson; Tore Saxne; Agneta Scheja; Izabela Bartosik; Thomas Mandl; Roger Hesselstrand
Journal:  Arthritis Res Ther       Date:  2014-02-06       Impact factor: 5.156

9.  Fecal Calprotectin, Elastase, and Alpha-1-Antitrypsin Levels After Roux-en-Y Gastric Bypass; Calprotectin Is Significantly Elevated in the Majority of Patients.

Authors:  Thomas C C Boerlage; Floris Westerink; Dennis C W Poland; Inge L Huibregtse; Yair I Z Acherman; Victor E A Gerdes
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

10.  Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch-Schönlein purpura patients: a retrospective analysis.

Authors:  Eun Young Paek; Dae Yong Yi; Ben Kang; Byung-Ho Choe
Journal:  BMC Pediatr       Date:  2020-08-08       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.